Related Experiment Videos
Renal tolerance of AMI 25.
G Brillet1, M Dubois, H Beaufils
1Department of Nephrology, Hôpital de la Pitie, Paris, France.
Investigative Radiology
|October 1, 1991
Summary
The new magnetic resonance contrast agent, AMI 25, demonstrated no kidney toxicity in a rat model, even at ten times the human dose. This finding is crucial for evaluating its safety in clinical liver lesion detection.
Area of Science:
- Nephrology
- Radiology
- Pharmacology
Background:
- Magnetic resonance imaging (MRI) contrast agents require rigorous safety evaluation.
- AMI 25 is a novel contrast agent targeting the reticuloendothelial system for liver lesion detection.
- Assessing renal tolerance is critical for systemic contrast agent administration.
Purpose of the Study:
- To evaluate the renal tolerance of the novel MRI contrast agent, AMI 25.
- To determine the nephrotoxicity of AMI 25 in a validated animal model of acute renal failure.
Main Methods:
- A rat model of acute renal failure was induced via renal ischemia and diatrizoate infusion.
- AMI 25 was administered intra-arterially at 1 ml/kg, a dose 10x higher than clinical use.
- Renal function was assessed by serum creatinine, creatinine clearance, and urinary N-acetyl glucosaminidase (NAG) excretion.
- Histological examination of kidney tissues was performed.
Main Results:
- AMI 25 administration did not alter serum creatinine, creatinine clearance, or urinary NAG excretion.
- No renal abnormalities were observed in histological analyses of kidneys treated with AMI 25.
- In contrast, diatrizoate induced acute tubular necrosis in a significant portion of the control group.
Conclusions:
- AMI 25 exhibits excellent renal tolerance in a rat model, even at supra-therapeutic doses.
- The study supports the potential safety of AMI 25 for clinical use in liver lesion detection via MRI.
- AMI 25 demonstrates a favorable nephrotoxicity profile compared to iodinated contrast agents in this model.